Высокоинтенсивная фокусированная ультразвуковая терапия в лечении больных десмоидной фибромой

Закрыть метаданные

До настоящего времени десмоидная фиброма остается достаточно редкой опухолью, с чем связано наличие значительных сложностей при изучении этой патологии. Несмотря на отсутствие потенциала к метастазированию, указанные опухоли отличаются агрессивным местно-деструктивным ростом, низкой чувствительностью к терапии, частым рецидивированием и выраженным влиянием на функциональный статус пациентов. Сегодня основными вариантами лечения десмоидной фибромы являются резекционное оперативное вмешательство, лучевая и системная лекарственная терапия. При этом все активнее изучаются возможности применения различных методов физической деструкции, одним из которых стала высокоинтенсивная фокусированная ультразвуковая терапия. В настоящей работе представлены современные данные по эпидемиологии, анатомии и морфологии десмоидных опухолей, а также широко описан опыт зарубежных исследователей, посвященный эффективности и безопасности проведения высокоинтенсивной фокусированной ультразвуковой терапии на аппаратах разного типа у больных десмоидной фибромой различной локализации.

Ключевые слова:

десмоидная фиброма

агрессивный фиброматоз

высокоинтенсивная фокусированная ультразвуковая терапия

HIFU-терапия

MRgHIFU

USgHIFU

Авторы:

Москвичева Л.И.

Московский научно-исследовательский онкологический институт им. П.А. Герцена — филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России

ORCID: 0000-0002-5750-8492

Дата поступления:

12.04.2023

Дата принятия в печать:

02.05.2023

Список литературы:

Martínez Trufero J, Pajares Bernad I, Torres Ramón I, Hernando Cubero J, Pazo Cid R. Desmoid-type fibromatosis: who, when, and how to treat. Curr Treat Options Oncol. 2017;18(5):29. https://doi.org/10.1007/s11864-017-0474-0
Kasper B. The EORTC QLQ-C30 summary score as a prognostic factor for survival of patients with cancer: a commentary. Oncologist. 2020;25(4):610-611. https://doi.org/10.1634/theoncologist.2019-0749
van Broekhoven DL, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823. https://doi.org/10.1245/s10434-015-4632-y
Li Destri G, Ferraro MJ, Calabrini M, Pennisi M. Magro G. Desmoid-type fibromatosis of the mesentery: report of a sporadic case with emphasis on differential diagnostic problems. Case Rep Med. 2014;2014:850180. https://doi.org/10.1155/2014/850180
Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96-107. https://doi.org/10.1016/j.ejca.2019.11.013
Koskenvuo L, Ristimäki A, Lepistö A. Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol. 2017;116(6):716-721. https://doi.org/10.1002/jso.24699
Saito Y, Hinoi T, Ueno H, Kobayashi H, Konishi T, Ishida F, Yamaguchi T, Inoue Y, Kanemitsu Y, Tomita N, et al. Risk factors for the development of desmoid tumor after colectomy in patients with familial adenomatous polyposis: multicenter retrospective cohort study in Japan. Ann Surg Oncol. 2016;23(suppl 4):559-565. https://doi.org/10.1245/s10434-016-5380-3
Sanchez-Mete L, Ferraresi V, Caterino M, Martayan A, Terrenato I, Mannisi E, Stigliano V. Desmoid tumors characteristics, clinical management, active surveillance, and description of our FAP case series. J Clin Med. 2020;9(12):4012. https://doi.org/10.3390/jcm9124012
De Marchis M, Tonelli F, Quaresmini D, Lovero D, Della-Morte D, Silvestris F, Guadagni F, Palmirotta R. Desmoid tumors in familial adenomatous polyposis. Anticancer Res. 2017;37(7):3357-3366. https://doi.org/10.21873/anticanres.11702
Nieuwenhuis MH, Lefevre JH, Bülow S, Järvinen H, Bertario L, Kernéis S, Parc Y, Vasen HF. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum. 2011;54(10):1229-1234. https://doi.org/10.1097/DCR.0b013e318227e4e8
Ratan R, Roland CL, Bishop AJ. Desmoid fibromatosis: management in an era of increasing options. Curr Oncol Rep. 2021;23(4):41. https://doi.org/10.1007/s11912-021-01026-w
Garcia-Ortega DY, Martín-Tellez KS, Cuellar-Hubbe M, Martínez-Said H, Álvarez-Cano A, Brener-Chaoul M, Alegría-Baños JA, Martínez-Tlahuel JL. Desmoid-type fibromatosis. Cancers (Basel). 2020;12(7):1851. https://doi.org/10.3390/cancers12071851
Cojocaru E, Gennatas S, Thway K, Fisher C, Smrke A, Strauss D, Hayes A, Smith M, Jones RL, Benson C, McVeigh TP. Approach to screening for Familial Adenomatous Polyposis (FAP) in a cohort of 226 patients with Desmoid-type Fibromatosis (DF): experience of a specialist center in the UK. Fam Cancer. 2022;21(1):69-74. https://doi.org/10.1007/s10689-021-00230-8
Slowik V, Attard T, Dai H, Shah R, Septer S. Desmoid tumors complicating familial adenomatous polyposis: a meta-analysis mutation spectrum of affected individuals. BMC Gastroenterol. 2015;15:84. https://doi.org/10.1186/s12876-015-0306-2
Crago AM, Chmielecki J, Rosenberg M, O’Connor R, Byrne C, Wilder FG, Thorn K, Agius P, Kuk D, Socci ND, et al. Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer. 2015;54(10):606-615. https://doi.org/10.1002/gcc.22272
Ophir G, Sivan S, Hana S, Guy R, Nathan G, Naomi FI, Joseph K, Ido W, Ofer M, Yael G, et al. Abdominal desmoid: course, severe outcomes, and unique genetic background in a large local series. Cancers (Basel). 2021;13(15):3673. https://doi.org/10.3390/cancers13153673
Kasper B, Raut CP, Gronchi A. Desmoid tumors: to treat or not to treat, That is the question. Cancer. 2020;126(24):5213-5221. https://doi.org/10.1002/cncr.33233
Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc. 2017;92(6):947-964. https://doi.org/10.1016/j.mayocp.2017.02.012
Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Ann Oncol. 2017;28(10):2399-2408. https://doi.org/10.1093/annonc/mdx323
Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, Salas S, Isambert N, Boudou-Rouquette P, Honore C, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125-131. https://doi.org/10.1016/j.ejca.2017.06.017
Choi SH, Yoon HI, Kim SH, Kim SK, Shin KH, Suh CO. Optimal radiotherapy strategy for primary or recurrent fibromatosis and long-term results. PLoS One. 2018;13(5):e0198134. https://doi.org/10.1371/journal.pone.0198134
Janssen ML, van Broekhoven DL, Cates JM, Bramer WM, Nuyttens JJ, Gronchi A, Salas S, Bonvalot S, Grünhagen DJ, Verhoef C. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. Br J Surg. 2017;104(4):347-357. https://doi.org/10.1002/bjs.10477
Bishop AJ, Zarzour MA, Ratan R, Torres KE, Feig BW, Wang WL, Lazar AJ, Moon BS, Roland CL, Guadagnolo BA. Long-term outcomes for patients with desmoid fibromatosis treated with radiation therapy: a 10-year update and re-evaluation of the role of radiation therapy for younger patients. Int J Radiat Oncol Biol Phys. 2019;103(5):1167-1174. https://doi.org/10.1016/j.ijrobp.2018.12.012
Bishop AJ, Landry JP, Roland CL, Ratan R, Feig BW, Moon BS, Zarzour MA, Wang WL, Lazar AJ, Lewis VO, et al. Certain risk factors for patients with desmoid tumors warrant reconsideration of local therapy strategies. Cancer. 2020;126(14):3265-3273. https://doi.org/10.1002/cncr.32921
Gronchi A, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm — a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014;25(3):578-583. https://doi.org/10.1093/annonc/mdt485
Болотина Л.В., Новикова О.В., Прокофьева Е.А. Роль химиотерапии в лечении агрессивного фиброматоза. Онкология. Журнал им. П.А. Герцена. 2012;1(3):72-76.
Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, et al. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in a large series of patients affected by desmoid-type fibromatosis. Cancer J. 2017;23(2):86-91. https://doi.org/10.1097/PPO.0000000000000254
Chugh R, Wathen JK, Patel SR, Maki RG, Meyers PA, Schuetze SM, Priebat DA, Thomas DG, Jacobson JA, Samuels BL, et al.; Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884-4891. https://doi.org/10.1158/1078-0432.CCR-10-1177
Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, et al. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019;20(9):1263-1272. https://doi.org/10.1016/S1470-2045(19)30276-1
Kummar S, O’Sullivan Coyne G, Do KT, Turkbey B, Meltzer PS, Polley E, Choyke PL, Meehan R, Vilimas R, Horneffer Y, et al. Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis). J Clin Oncol. 2017;35(14):1561-1569. https://doi.org/10.1200/JCO.2016.71.1994
Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, Gupta AA, Milhem MM, Conry RM, Movva S, et al. Sorafenib for advanced and refractory desmoid tumors. N Engl J Med. 2018;379(25):2417-2428. https://doi.org/10.1056/NEJMoa1805052
Testa S, Bui NQ, Charville GW, Avedian RS, Steffner R, Ghanouni P, Mohler DG, Ganjoo KN. Management of patients with newly diagnosed desmoid tumors in a first-line setting. Cancers (Basel). 2022;14(16):3907. https://doi.org/10.3390/cancers14163907
Mikhael R, Smith M, Tzanis D, Watson S, Miah AB, Bonvalot S. Desmoid tumors: who, when and how to treat? Curr Opin Oncol. 2022;34(4):335-341. https://doi.org/10.1097/CCO.0000000000000854
Москвичева Л.И., Сидоров Д.В., Ложкин М.В., Петров Л.О., Забелин М.В. Современные методы абляции злокачественных новообразований печени. Исследования и практика в медицине. 2018;5(4):58-71. https://doi.org/10.17709/2409-2231-2018-5-4-6
Zhou MY, Bui NQ, Charville GW, Ghanouni P, Ganjoo KN. Current management and recent progress in desmoid tumors. Cancer Treat Res Commun. 2022;31:100562. https://doi.org/10.1016/j.ctarc.2022.100562
Izadifar Z, Izadifar Z, Chapman D, Babyn P. An introduction to high intensity focused ultrasound: systematic review on principles, devices, and clinical applications. J Clin Med. 2020;9(2):460. https://doi.org/10.3390/jcm9020460
Москвичева Л.И. Высокоинтенсивная фокусированная ультразвуковая абляция злокачественных новообразований молочной железы. Исследования и практика в медицине. 2018;5(3):67-76. https://doi.org/10.17709/2409-2231-2018-5-3-6
Siedek F, Yeo SY, Heijman E, Grinstein O, Bratke G, Heneweer C, Puesken M, Persigehl T, Maintz D, Grüll H. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU): technical background and overview of current clinical applications (Part 1). Rofo. 2019;191(6):522-530. https://doi.org/10.1055/a-0817-5645
Elhelf IAS, Albahar H, Shah U, Oto A, Cressman E, Almekkawy M. High intensity focused ultrasound: the fundamentals, clinical applications and research trends. Diagn Interv Imaging. 2018;99(6):349-359. https://doi.org/10.1016/j.diii.2018.03.001
Болотина Л.В., Москвичева Л.И., Корниецкая А.Л., Сидоров Д.В., Гришин Н.А., Ложкин М.В., Каприн А.Д. Предварительная оценка эффективности комбинированного лечения с включением HIFU-терапии у больных раком поджелудочной железы. Сибирский онкологический журнал. 2021;20(3):18-27. https://doi.org/10.21294/1814-4861-2021-20-3-18-27
Москвичева Л.И. Применение HIFU-терапии в онкологии (2000-2021 гг.). Онкология. Журнал им. П.А. Герцена. 2022;11(1):64-74. https://doi.org/10.17116/onkolog20221101164
Wang Y, Wang W, Tang J. Ultrasound-guided high intensity focused ultrasound treatment for extra-abdominal desmoid tumours: preliminary results. Int J Hyperthermia. 2011;27(7):648-653. https://doi.org/10.3109/02656736.2011.597047
Zhao WP, Han ZY, Zhang J, Yu XL, Cheng ZG, Zhou X, Liang P. Early experience: high-intensity focused ultrasound treatment for intra-abdominal aggressive fibromatosis of failure in surgery. Br J Radiol. 2016;89(1062):20151026. https://doi.org/10.1259/bjr.20151026
Zhang R, Chen JY, Zhang L, Li KQ, Xiao ZB, Mo SJ, Chen L, Chen WZ. The safety and ablation efficacy of ultrasound-guided high-intensity focused ultrasound ablation for desmoid tumors. Int J Hyperthermia. 2021;38(2):89-95. https://doi.org/10.1080/02656736.2021.1894359
Zhong X, Hu X, Zhao P, Wang Y, Fang XF, Shen J, Shen H, Yuan Y. The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor. Cancer Med. 2022;11(10):2079-2084. https://doi.org/10.1002/cam4.4573
Yang Y, Zhang J, Pan Y. Management of unresectable and recurrent intra-abdominal desmoid tumors treated with ultrasound-guided high-intensity focused ultrasound: a retrospective single-center study. Medicine (Baltimore). 2022;101(34):e30201. https://doi.org/10.1097/MD.0000000000030201
Ghanouni P, Dobrotwir A, Bazzocchi A, Bucknor M, Bitton R, Rosenberg J, Telischak K, Busacca M, Ferrari S, Albisinni U, et al. Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study. Eur Radiol. 2017;27(2):732-740. https://doi.org/10.1007/s00330-016-4376-5
Najafi A, Fuchs B, Binkert CA. Mid-term results of MR-guided high-intensity focused ultrasound treatment for relapsing superficial desmoids. Int J Hyperthermia. 2019;36(1):538-542. https://doi.org/10.1080/02656736.2019.1608376

Закрыть метаданные